CENTENE ANNOUNCES BOARD OF DIRECTORS CHANGES

Rhea-AI Summary

Centene (NYSE: CNC) announced that Kenneth A. Burdick retired from its Board of Directors, effective July 28, 2026, and that Paul J. Diaz has been appointed to the Board, also effective that date. Burdick joined the Board in January 2022 after serving as Centene’s Executive Vice President of Products and Markets and previously as CEO of WellCare Health Plans.

Diaz is Managing Partner at Cressey & Company and formerly served as President and CEO of Myriad Genetics and Kindred Healthcare. He has served on several healthcare company boards, including DaVita and PharMerica, and is expected by Centene to contribute extensive healthcare leadership and governance experience.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ST. LOUIS, July 28, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced that Kenneth A. Burdick has retired from the Company's Board of Directors, effective July 28, 2026, and that Paul J. Diaz has been appointed to the Board, effective July 28, 2026.

Mr. Burdick joined Centene's Board of Directors in January 2022 and has provided valuable insight and guidance leveraging his decades-long leadership in healthcare. Prior to joining the Board, he served as Executive Vice President of Products and Markets at Centene and before that was the Chief Executive Officer of WellCare Health Plans.

Mr. Diaz is a Managing Partner at Cressey & Company, a private investment firm focused on investing and cultivating high-quality healthcare firms. He previously served as President and Chief Executive Officer of Myriad Genetics, Inc., a leading genetic testing and precision medicine company. Before that, he served as President and Chief Executive Officer of Kindred Healthcare, a Fortune 500 healthcare services company. Mr. Diaz also brings extensive public company board experience, having served on the boards of several healthcare organizations, including DaVita and PharMerica.

"After careful consideration, I have decided the time is right to step down from the Centene Board to focus on personal priorities and other opportunities," said Mr. Burdick. "It has been a privilege to serve Centene and support its mission of transforming the health of the communities it serves, one person at a time. I have great confidence in the Company's leadership, strategy and future, and I leave knowing it is well positioned for its next chapter of growth and impact."

"Ken has been a valued member of our Board. His deep industry expertise, strategic perspective, and commitment to improving healthcare have made a meaningful impact on Centene. On behalf of the Board, we thank him for his service and wish him all the best in retirement," said Frederick H. Eppinger, Chair of Centene's Board of Directors. "We are also pleased to welcome Paul Diaz to the Board. His extensive healthcare leadership experience, public company governance expertise and record of guiding organizations through growth and transformation will bring valuable perspective as Centene continues to advance its strategy and serve its members."

"I am honored to join Centene's Board of Directors and support a company with such a strong mission and commitment to improving the health of the communities it serves," said Mr. Diaz. "I look forward to drawing on my experience across the healthcare industry to help advance innovation, strengthen access to high-quality care and support Centene's continued impact for its members and stakeholders."

About Centene Corporation 
Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach with local teams to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured individuals. Centene offers affordable and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace. 

Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, http://investors.centene.com/.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/centene-announces-board-of-directors-changes-302835967.html

SOURCE Centene Corporation

FAQ

What board of directors changes did Centene (NYSE: CNC) announce on July 28, 2026?

Centene announced that Kenneth A. Burdick retired from its Board and that Paul J. Diaz was appointed, both effective July 28, 2026. According to Centene, this refresh adds additional healthcare leadership and governance experience to its board.

Who is leaving Centene’s (CNC) board of directors and when is the retirement effective?

Kenneth A. Burdick is retiring from Centene’s Board of Directors, effective July 28, 2026. According to Centene, Burdick joined the board in January 2022 and previously held senior executive roles at Centene and WellCare Health Plans.

Who is Paul J. Diaz, the new Centene (CNC) board member appointed in July 2026?

Paul J. Diaz is Centene’s newly appointed board member, effective July 28, 2026. According to Centene, he is Managing Partner at Cressey & Company and former President and CEO of Myriad Genetics and Kindred Healthcare, with extensive healthcare board experience.

How might Paul J. Diaz’s background benefit Centene shareholders (CNC)?

Paul J. Diaz brings extensive healthcare leadership and public company board experience, which may strengthen Centene’s governance. According to Centene, his record of guiding organizations through growth and transformation should support the company’s strategy and service to its members.

Why did Kenneth A. Burdick decide to retire from Centene’s board?

Kenneth A. Burdick said he stepped down to focus on personal priorities and other opportunities. According to Centene, he expressed confidence in the company’s leadership, strategy, and future as he retired from the board effective July 28, 2026.

Does the Centene (CNC) board change affect the company’s strategic direction?

Centene did not announce a change in strategic direction with this board move. According to Centene, Paul J. Diaz’s experience in healthcare growth and transformation is expected to provide valuable perspective as the company continues to advance its existing strategy.